Tikehau Capital, a pan-European alternative asset management and investment company, and SPRIM Ventures, a medical and scientific consultancy firm, has held the initial closing of their first venture capital fund, TKS1, which will focus on early stage investments in med-tech and life science companies. Total committed capital for the fund as of its initial closing is USD50 million.
This unique partnership combines Tikehau Capital’s background in pioneering new initiatives and proven successful investment track record with SPRIM’s domain expertise and experience in the healthcare industry.
Administered out of Singapore and with investment sizes ranging between USD500,000 and USD5 million, TKS1 provides early stage capital to innovative companies offering solutions that move science forward in the health sector, contribute to the transition from intervention to prediction, diagnosis and monitoring while enabling life science companies globally to develop therapeutics faster and more economically.
